The $1,000 genome was a worthy cause that helped motivate scientists and engineers to drive down the cost of decoding DNA, but now there are numerous steps needed to analyze the data from sequenced genomes to deliver personalized care for patients with cancer and other diseases.
Microsoft ($MSFT) has plans to step up its focus on social networking with its expected buyout of the business social network Yammer for more than $1 billion. And The Wall Street Journal caught up with the tech chief at AstraZeneca, among others, in a piece that gauges the import of the major buyout across several different sectors.
Compugen has found a new use for its computational discovery technologies. The Tel Aviv, Israel-based company ($CGEN) and global drugmaker Merck Serono have joined forces to form a startup called Neviah Genomics, which will focus on developing diagnostic tests to spot drug-induced toxicities, which cause drugs to fail in clinical trials.
It's time for the DIA 2012 Annual Meeting. For the next couple days, I'll be in historic Philadelphia to attend a slew of meetings with purveyors of life sciences software and panels on hot topics such as patient recruitment for clinical trials and integration of electronic health records (EHRs) and electronic data capture (EDC) systems.
Drugmakers hunt far and wide for patients to take part in their clinical trials, making study recruitment one of the trickiest and time-consuming aspects of product development. Now the software giant Oracle ($ORCL) has set up cloud-based applications that aim to ease the burden of rounding up qualified subjects for clinical studies.
The Palo Alto, CA-based startup has announced a cloud-based version of its software for analyzing and visualizing clinical trial data.
Social media has already proven to be a useful tool to get out the word to potential participants about new clinical trials, but a soup-to-nuts approach to online recruitment and enrollment in a Pfizer study has failed.
Parexel unveiled its "MyTrials" platform as a way to integrate a bevy of software tools that the company and its pharma sponsors use in conducting studies.
Sub-Saharan Africa has suffered a drug safety meltdown. A new survey found that only four out of 46 countries in the region had adequate systems to pinpoint and react to problems with drug safety. Officials are prescribing a coordinated regional effort to bring pharmacovigilance up to snuff, and a new mobile tech system for reporting bad drug reactions in Nigeria is already in the works.
A massive research effort has explored the vast number of microbes that live on and inside our bodies, amassing an incredible amount of data on the microbial genes that dwarfs the information from a human genome.
Recently launched with a $40.7 million round of funding from Third Rock Ventures, the Global Blood Therapeutics plans to harness the power of its tech platform--called SHAPE--to combat blood diseases.
Silicon Valley Biosystems has emerged from top-secret status this week with bold plans to provide doctors with high-quality reports on their patients' genomes, challenging a growing crowd of software companies with similar goals, Bio-IT World's veteran editor Kevin Davies reported.
Syapse has pushed its software for aggregating and structuring biomedical data into the commercial realm.
Harvard Medical School has named Rainer Fuchs as the prestigious institution's chief information officer, a post that Dr. John Halamka had recently vacated, FierceBiotech IT has confirmed after learning of the news on Twitter last week.
The Twittersphere is lousy with pharma feeds. Count them up, as Eye on FDA recently did, and 44 drugmakers operate 200 Twitter accounts, and the number appears to be growing as pharma companies raise their online profiles and tailor their social media strategies.
Swiss drug giant Novartis ($NVS) and researchers from the startup SeaChange Pharmaceuticals and the University of California, San Francisco, have shown that their computational strategy can predict "off-target" problems before human testing.
Eli Lilly has discovered a new use for mobile apps--informing doctors about clinical trials for cancer drugs.
GenomOncology has jumped into the race to analyze genetic data for cancer specialists. With applications in pharma and research labs and oncology clinics, the company's "genomic-analysis-as-service" plan has attracted a $250,000 commitment from the nonprofit venture group JumpStart.
Complete Genomics is slumping. The provider of whole genome sequencing and informatics support has decided to cut about 20% of its roster to conserve cash, and the company has hired a financial adviser to aid its hunt for "strategic alternatives."
Researchers have tapped computers to engineer proteins that bind to the flu in a way that prevents the virus from horning in on cells. And the proteins hone in on an area of the virus that makes them able to stymie multiple flu strains, according to a report from the University of Washington (UW).